Schering-Plough Shows Off Once-Daily Hep C Drug Narlaprevir At AASLD
This article was originally published in The Pink Sheet Daily
Executive Summary
Next-generation ritonavir-boosted protease inhibitor is headed into Phase IIb, and if all goes well, could be a significant player in the hepatitis C market.
You may also be interested in...
Vertex's Telaprevir Works In Twice Daily Dose; Response-Guided Therapy Cuts Down Drop-Outs
Is it a trick or a treat? AASLD lifts embargo on all annual meeting data at Halloween press conference.
INFORM-1 Data Show Potential Efficacy And Safety Of Roche HCV Combo
Combination therapy with two experimental, oral, direct-acting antivirals in treatment-naïve hepatitis C patients showed significant viral-load reductions and a clean safety profile, Roche and its biotech partners on the two drugs announced April 25 during the European Association for the Study of the Liver conference in Copenhagen, Denmark
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.